{"id":"NCT00536510","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Effect of MK0524A on Cholesterol Levels (0524A-048)","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Lipid-Altering Efficacy and Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2008-03","completion":"2008-03","firstPosted":"2007-09-27","resultsPosted":"2009-05-13","lastUpdate":"2015-09-02"},"enrollment":646,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia","Hyperlipidemia"],"interventions":[{"type":"DRUG","name":"laropiprant/niacin (MK0524A)","otherNames":["MK0524A"]},{"type":"DRUG","name":"Comparator: placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the study is to assess the effects of MK0524A in reducing cholesterol levels in an Asian population.","primaryOutcome":{"measure":"Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) After 12 Weeks","timeFrame":"12 weeks","effectByArm":[{"arm":"MK0524A 2 g","deltaMin":-10.3,"sd":null},{"arm":"Placebo","deltaMin":4.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21291812"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":321},"commonTop":["Flushing","Pruritus","Creatine Phosphokinase Increased","Alanine Aminotransferase Increased","Upper Respiratory Tract Infection"]}}